Literature DB >> 32038914

Improving outcomes for brain metastases in EGFR mutated NSCLC.

Jennifer W Carlisle1, Suresh S Ramalingam1.   

Abstract

Entities:  

Year:  2019        PMID： 32038914      PMCID： PMC6987335          DOI： 10.21037/tlcr.2019.05.08

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  21 in total

1.  Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

Authors:  Stephanie Heon; Beow Y Yeap; Gregory J Britt; Daniel B Costa; Michael S Rabin; David M Jackman; Bruce E Johnson
Journal:  Clin Cancer Res       Date:  2010-10-28       Impact factor: 12.531

2.  Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.

Authors:  Yosuke Togashi; Katsuhiro Masago; Satohiro Masuda; Tomoyuki Mizuno; Masahide Fukudo; Yasuaki Ikemi; Yuichi Sakamori; Hiroki Nagai; Young Hak Kim; Toshiya Katsura; Michiaki Mishima
Journal:  Cancer Chemother Pharmacol       Date:  2012-07-18       Impact factor: 3.333

3.  Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

Authors:  Deepa Rangachari; Norihiro Yamaguchi; Paul A VanderLaan; Erik Folch; Anand Mahadevan; Scott R Floyd; Erik J Uhlmann; Eric T Wong; Suzanne E Dahlberg; Mark S Huberman; Daniel B Costa
Journal:  Lung Cancer       Date:  2015-02-04       Impact factor: 5.705

4.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

5.  CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Thanyanan Reungwetwattana; Kazuhiko Nakagawa; Byoung Chul Cho; Manuel Cobo; Eun Kyung Cho; Alessandro Bertolini; Sabine Bohnet; Caicun Zhou; Ki Hyeong Lee; Naoyuki Nogami; Isamu Okamoto; Natasha Leighl; Rachel Hodge; Astrid McKeown; Andrew P Brown; Yuri Rukazenkov; Suresh S Ramalingam; Johan Vansteenkiste
Journal:  J Clin Oncol       Date:  2018-08-28       Impact factor: 44.544

6.  Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  D Ross Camidge; Hye Ryun Kim; Myung-Ju Ahn; James Chih-Hsin Yang; Ji-Youn Han; Jong-Seok Lee; Maximilian J Hochmair; Jacky Yu-Chung Li; Gee-Chen Chang; Ki Hyeong Lee; Cesare Gridelli; Angelo Delmonte; Rosario Garcia Campelo; Dong-Wan Kim; Alessandra Bearz; Frank Griesinger; Alessandro Morabito; Enriqueta Felip; Raffaele Califano; Sharmistha Ghosh; Alexander Spira; Scott N Gettinger; Marcello Tiseo; Neeraj Gupta; Jeff Haney; David Kerstein; Sanjay Popat
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

7.  Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.

Authors:  Myung-Ju Ahn; Chun-Ming Tsai; Frances A Shepherd; Lyudmila Bazhenova; Lecia V Sequist; Toyoaki Hida; James C H Yang; Suresh S Ramalingam; Tetsuya Mitsudomi; Pasi A Jänne; Helen Mann; Mireille Cantarini; Glenwood Goss
Journal:  Cancer       Date:  2018-12-04       Impact factor: 6.860

8.  Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

Authors:  Peter Ballard; James W T Yates; Zhenfan Yang; Dong-Wan Kim; James Chih-Hsin Yang; Mireille Cantarini; Kathryn Pickup; Angela Jordan; Mike Hickey; Matthew Grist; Matthew Box; Peter Johnström; Katarina Varnäs; Jonas Malmquist; Kenneth S Thress; Pasi A Jänne; Darren Cross
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

10.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245
View more
  2 in total

1.  High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.

Authors:  A J Piper-Vallillo; Julia K Rotow; Jacqueline V Aredo; Khvaramze Shaverdashvili; Jia Luo; Jennifer W Carlisle; Hatim Husain; Alona Muzikansky; Rebecca S Heist; Deepa Rangachari; Suresh S Ramalingam; Heather A Wakelee; Helena A Yu; Lecia V Sequist; Joshua M Bauml; Joel W Neal; Zofia Piotrowska
Journal:  JTO Clin Res Rep       Date:  2022-04-21

Review 2.  Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.

Authors:  Agnieszka Rybarczyk-Kasiuchnicz; Rodryg Ramlau; Katarzyna Stencel
Journal:  Int J Mol Sci       Date:  2021-01-08       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.